DE60003577D1 - Kristalle eines oximinoalkansäure-derivates und ihre verwendung als antidiabetika - Google Patents

Kristalle eines oximinoalkansäure-derivates und ihre verwendung als antidiabetika

Info

Publication number
DE60003577D1
DE60003577D1 DE60003577T DE60003577T DE60003577D1 DE 60003577 D1 DE60003577 D1 DE 60003577D1 DE 60003577 T DE60003577 T DE 60003577T DE 60003577 T DE60003577 T DE 60003577T DE 60003577 D1 DE60003577 D1 DE 60003577D1
Authority
DE
Germany
Prior art keywords
oximinoalkanic
antidiabetics
crystals
derivatives
oximinoalkanic derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60003577T
Other languages
English (en)
Other versions
DE60003577T2 (de
Inventor
Yu Momose
Hiroshi Imoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE60003577D1 publication Critical patent/DE60003577D1/de
Publication of DE60003577T2 publication Critical patent/DE60003577T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60003577T 1999-10-29 2000-10-26 Kristalle eines oximinoalkansäure-derivates und ihre verwendung als antidiabetika Expired - Fee Related DE60003577T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP30834699 1999-10-29
JP30834699 1999-10-29
PCT/JP2000/007482 WO2001032637A1 (en) 1999-10-29 2000-10-26 Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics

Publications (2)

Publication Number Publication Date
DE60003577D1 true DE60003577D1 (de) 2003-07-31
DE60003577T2 DE60003577T2 (de) 2004-04-29

Family

ID=17979966

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60003577T Expired - Fee Related DE60003577T2 (de) 1999-10-29 2000-10-26 Kristalle eines oximinoalkansäure-derivates und ihre verwendung als antidiabetika

Country Status (19)

Country Link
US (1) US6777435B1 (de)
EP (1) EP1224178B1 (de)
KR (1) KR100433885B1 (de)
CN (1) CN1407975A (de)
AR (1) AR031078A1 (de)
AT (1) ATE243684T1 (de)
AU (1) AU7958100A (de)
CA (1) CA2388200A1 (de)
CL (1) CL2000002938A1 (de)
CO (1) CO5261530A1 (de)
DE (1) DE60003577T2 (de)
HK (1) HK1044536A1 (de)
HU (1) HUP0203884A3 (de)
MY (1) MY135840A (de)
NO (1) NO20022007L (de)
PE (1) PE20010761A1 (de)
PL (1) PL364171A1 (de)
TW (1) TW558554B (de)
WO (1) WO2001032637A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403903A1 (en) * 2000-03-28 2002-09-26 Masatoshi Hazama Angiogenesis inhibitors
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
CA2443325C (en) * 2001-04-04 2011-06-14 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
US7217697B2 (en) 2001-05-30 2007-05-15 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor
TWI327462B (en) * 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
CA2489145A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited Insulin-sensitizing agent
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
AU2005289808B2 (en) * 2004-09-24 2011-11-03 The Government Of The United States As Represented By The Secretary Of The Army, U.S. Army Medical Research Institute Of Chemical Defense Method of treating organophosphorous poisoning
US20090181887A1 (en) * 2005-09-08 2009-07-16 Gastrotech Pharma A/S Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
CA2937107C (en) * 2014-01-17 2020-12-22 Cornell University Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
KR102281228B1 (ko) 2019-09-03 2021-07-22 신창수 과수나무의 가지지지용 파이프클램프

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139470A0 (en) * 1998-05-11 2001-11-25 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives
CA2389208A1 (en) * 1999-10-29 2001-05-10 Takeda Chemical Industries, Ltd. Process for the preparation of oxyiminoalkanoic acid derivatives

Also Published As

Publication number Publication date
CL2000002938A1 (es) 2009-05-15
MY135840A (en) 2008-07-31
CO5261530A1 (es) 2003-03-31
DE60003577T2 (de) 2004-04-29
PE20010761A1 (es) 2001-08-01
WO2001032637A1 (en) 2001-05-10
HUP0203884A2 (hu) 2003-03-28
NO20022007L (no) 2002-06-24
AU7958100A (en) 2001-05-14
KR20010102429A (ko) 2001-11-15
AR031078A1 (es) 2003-09-10
TW558554B (en) 2003-10-21
ATE243684T1 (de) 2003-07-15
EP1224178B1 (de) 2003-06-25
CN1407975A (zh) 2003-04-02
CA2388200A1 (en) 2001-05-21
PL364171A1 (en) 2004-12-13
KR100433885B1 (ko) 2004-06-04
HUP0203884A3 (en) 2005-01-28
NO20022007D0 (no) 2002-04-26
EP1224178A1 (de) 2002-07-24
HK1044536A1 (en) 2002-10-25
US6777435B1 (en) 2004-08-17

Similar Documents

Publication Publication Date Title
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60139477D1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
DE60123461D1 (de) Salze eines 4-isothiazolcarboxamids und ihre verwendung als anti-hyperproliferationsmittel
DE50009607D1 (de) Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung
ATA5422000A (de) Oximderivate und ihre verwendung als latente säuren
DE60006580D1 (de) Benzazolderivate und ihre verwendung als jnk modulatoren
DE69836346D1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
DE69926800D1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
ATE299503T1 (de) Pyridin-3-carbonsäurederivate und ihre verwendung als zwischenprodukte
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE60003577D1 (de) Kristalle eines oximinoalkansäure-derivates und ihre verwendung als antidiabetika
DE69826662D1 (de) 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
DE50008597D1 (de) Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
DE60030574D1 (de) Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60017376D1 (de) Carbaminsäurederivate und ihre verwendung als liganden von metabotropen glutamatrezeptoren
IS5582A (is) Meta-asahringamínóbensósýrusambönd og afleiður þeirra reynast mótlyf við integríni.
NO20022600L (no) Nye heterocykliske forbindelser og salter derav og medisinsk anvendelse av samme
DE69610316D1 (de) Piperazin-derivate und ihre verwendung als 5-ht1a-antagoniste
DE60037183D1 (de) Neue amidinbenzylamin-derivate und ihre verwendung als thrombin-inhibitoren
DE50003275D1 (de) Substituierte benzoylisoxazole und ihre verwendung als herbizide
DE69510228D1 (de) Piperidinessigsäurederivate und ihre verwendung als fibrinogenantagonistmittel
ATE264315T1 (de) Aminothiazolderivate und ihre verwendung als crf- rezeptor-liganden
DE59812664D1 (de) Fluorierte derivate des phenanthrens und ihre verwendung in flüssigkristallmischungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP

8339 Ceased/non-payment of the annual fee